Churg-Strauss syndrome

Karina A. Keogh, Ulrich Specks

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Churg-Strauss syndrome was originally called "allergic granulomatosis and angiitis," describing the combination of eosinophilic inflammation, extravascular granulomas, and necrotizing vasculitis occurring in patients with severe asthma. It is now classified as a small-vessel vasculitis and, together with Wegener's granulomatosis and microscopic polyangiitis, as one of the vasculitides associated with antineutrophil cytoplasmic autoantibodies (ANCA). Glucocorticoid-sparing agents used in the treatment of asthma, such as leukotriene receptor antagonists, may unmask this particular form of vasculitis as oral glucocorticoids are withdrawn. ANCA occur in 40-75% of patients with active disease and typically react with myeloperoxidase. Patients' symptoms are defined by various degrees of eosinophilic inflammation and necrotizing vasculitis, which may affect any organ. On presentation, Churg-Strauss syndrome needs to be differentiated from other eosinophilic pneumonias, idiopathic hypereosinophilic syndrome, and Wegener's granulomatosis and microscopic polyangiitis. Churg-Strauss syndrome remains a rare disease with a poorly understood pathogenesis. Treatment consists primarily of glucocortoids. Patients who have ANCA at the time of presentation should be treated according to the treatment principles for ANCA-associated vasculitides. However, the exact role of glucocorticoid-sparing immunosuppressive agents and treatment options for refractory disease remain poorly studied.

Original languageEnglish (US)
Pages (from-to)148-157
Number of pages10
JournalSeminars in Respiratory and Critical Care Medicine
Volume27
Issue number2
DOIs
StatePublished - Apr 2006

Fingerprint

Churg-Strauss Syndrome
Vasculitis
Autoantibodies
Microscopic Polyangiitis
Glucocorticoids
Granulomatosis with Polyangiitis
Asthma
Pulmonary Eosinophilia
Hypereosinophilic Syndrome
Inflammation
Leukotriene Antagonists
Therapeutics
Immunosuppressive Agents
Rare Diseases
Granuloma
Peroxidase

Keywords

  • ANCA
  • Asthma
  • Churg-Strauss syndrome
  • Eosinophilia
  • Leukotriene receptor antagonists
  • Vasculitis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine
  • Critical Care

Cite this

Churg-Strauss syndrome. / Keogh, Karina A.; Specks, Ulrich.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 27, No. 2, 04.2006, p. 148-157.

Research output: Contribution to journalArticle

Keogh, Karina A. ; Specks, Ulrich. / Churg-Strauss syndrome. In: Seminars in Respiratory and Critical Care Medicine. 2006 ; Vol. 27, No. 2. pp. 148-157.
@article{135a321bfa404fc58d68589f34bb199e,
title = "Churg-Strauss syndrome",
abstract = "Churg-Strauss syndrome was originally called {"}allergic granulomatosis and angiitis,{"} describing the combination of eosinophilic inflammation, extravascular granulomas, and necrotizing vasculitis occurring in patients with severe asthma. It is now classified as a small-vessel vasculitis and, together with Wegener's granulomatosis and microscopic polyangiitis, as one of the vasculitides associated with antineutrophil cytoplasmic autoantibodies (ANCA). Glucocorticoid-sparing agents used in the treatment of asthma, such as leukotriene receptor antagonists, may unmask this particular form of vasculitis as oral glucocorticoids are withdrawn. ANCA occur in 40-75{\%} of patients with active disease and typically react with myeloperoxidase. Patients' symptoms are defined by various degrees of eosinophilic inflammation and necrotizing vasculitis, which may affect any organ. On presentation, Churg-Strauss syndrome needs to be differentiated from other eosinophilic pneumonias, idiopathic hypereosinophilic syndrome, and Wegener's granulomatosis and microscopic polyangiitis. Churg-Strauss syndrome remains a rare disease with a poorly understood pathogenesis. Treatment consists primarily of glucocortoids. Patients who have ANCA at the time of presentation should be treated according to the treatment principles for ANCA-associated vasculitides. However, the exact role of glucocorticoid-sparing immunosuppressive agents and treatment options for refractory disease remain poorly studied.",
keywords = "ANCA, Asthma, Churg-Strauss syndrome, Eosinophilia, Leukotriene receptor antagonists, Vasculitis",
author = "Keogh, {Karina A.} and Ulrich Specks",
year = "2006",
month = "4",
doi = "10.1055/s-2006-939518",
language = "English (US)",
volume = "27",
pages = "148--157",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Churg-Strauss syndrome

AU - Keogh, Karina A.

AU - Specks, Ulrich

PY - 2006/4

Y1 - 2006/4

N2 - Churg-Strauss syndrome was originally called "allergic granulomatosis and angiitis," describing the combination of eosinophilic inflammation, extravascular granulomas, and necrotizing vasculitis occurring in patients with severe asthma. It is now classified as a small-vessel vasculitis and, together with Wegener's granulomatosis and microscopic polyangiitis, as one of the vasculitides associated with antineutrophil cytoplasmic autoantibodies (ANCA). Glucocorticoid-sparing agents used in the treatment of asthma, such as leukotriene receptor antagonists, may unmask this particular form of vasculitis as oral glucocorticoids are withdrawn. ANCA occur in 40-75% of patients with active disease and typically react with myeloperoxidase. Patients' symptoms are defined by various degrees of eosinophilic inflammation and necrotizing vasculitis, which may affect any organ. On presentation, Churg-Strauss syndrome needs to be differentiated from other eosinophilic pneumonias, idiopathic hypereosinophilic syndrome, and Wegener's granulomatosis and microscopic polyangiitis. Churg-Strauss syndrome remains a rare disease with a poorly understood pathogenesis. Treatment consists primarily of glucocortoids. Patients who have ANCA at the time of presentation should be treated according to the treatment principles for ANCA-associated vasculitides. However, the exact role of glucocorticoid-sparing immunosuppressive agents and treatment options for refractory disease remain poorly studied.

AB - Churg-Strauss syndrome was originally called "allergic granulomatosis and angiitis," describing the combination of eosinophilic inflammation, extravascular granulomas, and necrotizing vasculitis occurring in patients with severe asthma. It is now classified as a small-vessel vasculitis and, together with Wegener's granulomatosis and microscopic polyangiitis, as one of the vasculitides associated with antineutrophil cytoplasmic autoantibodies (ANCA). Glucocorticoid-sparing agents used in the treatment of asthma, such as leukotriene receptor antagonists, may unmask this particular form of vasculitis as oral glucocorticoids are withdrawn. ANCA occur in 40-75% of patients with active disease and typically react with myeloperoxidase. Patients' symptoms are defined by various degrees of eosinophilic inflammation and necrotizing vasculitis, which may affect any organ. On presentation, Churg-Strauss syndrome needs to be differentiated from other eosinophilic pneumonias, idiopathic hypereosinophilic syndrome, and Wegener's granulomatosis and microscopic polyangiitis. Churg-Strauss syndrome remains a rare disease with a poorly understood pathogenesis. Treatment consists primarily of glucocortoids. Patients who have ANCA at the time of presentation should be treated according to the treatment principles for ANCA-associated vasculitides. However, the exact role of glucocorticoid-sparing immunosuppressive agents and treatment options for refractory disease remain poorly studied.

KW - ANCA

KW - Asthma

KW - Churg-Strauss syndrome

KW - Eosinophilia

KW - Leukotriene receptor antagonists

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=33646443531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646443531&partnerID=8YFLogxK

U2 - 10.1055/s-2006-939518

DO - 10.1055/s-2006-939518

M3 - Article

C2 - 16612766

AN - SCOPUS:33646443531

VL - 27

SP - 148

EP - 157

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 2

ER -